Clinical trial
Intravenous And Oral Casopitant (GW679769) For The Prevention Of Chemotherapy…
NCT00366834 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00366834 |
|---|---|
| Title | Intravenous And Oral Casopitant (GW679769) For The Prevention Of Chemotherapy Induced Nausea And Vomiting |
| Official title | A Phase III, Multicenter, Randomized, Double-Blind, Active Controlled, Parallel Group Study of the Safety and Efficacy of the Intravenous and Oral Formulations of the Neurokinin-1 Receptor Antagonist Casopitant (GW679769) in Combination With Ondansetron and Dexamethasone for the Prevention of Nausea |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Vomiting, Nausea, Nausea and Vomiting, Chemotherapy-Induced |
| Intervention type | Drug |
| Interventions | Casopitant (GW679769) oral tablets, Casopitant (GW679769) intravenous, Dexamethasone intravenous, Ondansetron oral tablets, placebo |
| Enrollment | 1,840 |
| Start date | Jul 1, 2006 |
| Primary completion | Oct 1, 2007 |
| Completion | Oct 1, 2009 |
| First posted | Aug 21, 2006 |
| Last update posted | Sep 10, 2012 |
| Countries | Argentina, Austria, Belgium, Bulgaria, Canada, Croatia, Czechia, Denmark, Estonia, Germany, Greece, Hong Kong and 20 more |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: